Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)...
Non-Hodgkin LymphomaBurkitt's Lymphoma12 moreThis study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular...
Non-Hodgkin LymphomaThis open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma...
Adult Grade III Lymphomatoid GranulomatosisB-cell Chronic Lymphocytic Leukemia88 moreThis clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular...
Follicular LymphomaB-cell Lymphoma1 moreThis is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab,...
LymphomaThe purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
CD20 PositiveRecurrent B-Cell Non-Hodgkin Lymphoma1 moreThis partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment. Monoclonal antibodies, such as ipilimumab and rituximab, may interfere with the ability of cancer cells to grow and spread.
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma46 moreThis phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular Lymphoma3 moreThis pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Buparlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated,...
Low-grade B Cell Non-Hodgkin's LymphomaMantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not IndicatedThe purpose of this study is to assess the efficacy and safety of SyB L-0501 (two-day consecutive 90 mg/m2/day IV drip infusions) in combination with rituximab (375 mg/m2 IV drip infusion) on untreated, low-grade B cell non-Hodgkin's lymphoma and mantle cell lymphoma where hematopoietic stem cell transplantation is not indicated.
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level...
Non-Hodgkin Lymphoma (NHL)Cutaneous Lymphoma3 moreThe purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Despite a wide range of therapeutic options, the treatments are associated with short response duration, thus this condition is largely incurable. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting.